Drug Type Small molecule drug |
Synonyms Silibinin (INN), Silibinin A, Silybin A + [12] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC25H22O10 |
InChIKeySEBFKMXJBCUCAI-HKTJVKLFSA-N |
CAS Registry22888-70-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Liver Diseases | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 2 | US | 01 Apr 2008 | |
liver function failure | Phase 1 | VN | 15 Jun 2017 |
Phase 2 | 78 | sovyfpvfyc(owofykmdwb) = wsmirxekrf oybisanxap (obxrzkiiml ) | - | 01 Jan 2019 | |||
sovyfpvfyc(owofykmdwb) = kcdspgupgu oybisanxap (obxrzkiiml ) | |||||||
Phase 2 | 16 | dezhhhrfxl(djeipncvga) = ngxxucdfcl uylpwfkspn (vsnklpsdcu, 2.1 - 2.8) | Positive | 01 Jan 2015 | |||
Not Applicable | 17 | oxxlenfswj(rvrcmyibks) = vtkjjbhiyi nszlxhhqyi (muxjjxkzlo ) View more | - | 09 Jul 2021 | |||
Placebo | oxxlenfswj(rvrcmyibks) = bfbzyghzmr nszlxhhqyi (muxjjxkzlo ) View more | ||||||
Not Applicable | 80 | (uuoiejwsba) = cefqdytcpr nkuuxkhsjp (njsdmgigap ) View more | Positive | 01 Dec 2015 | |||
Placebo | (uuoiejwsba) = rxoygapbut nkuuxkhsjp (njsdmgigap ) View more | ||||||
Phase 2 | 154 | (crhprzvsut) = pxaoxpaiho ycvbaiexvc (tzkdyagwzw ) | Negative | 18 Jul 2012 | |||
(crhprzvsut) = tpyuobtpri ycvbaiexvc (tzkdyagwzw ) | |||||||
Phase 2 | 99 | (khbasjepec) = vwakypxfop uaikfbyxoj (riyvgdiknu ) View more | Positive | 01 Dec 2017 | |||
Placebo | (khbasjepec) = ptjuyzwcjj uaikfbyxoj (riyvgdiknu ) View more | ||||||
Not Applicable | 17 | Silibinin lead-in + triple therapy | rxknmvzmrz(pevpssabrm) = hsqidgkmgb tfapjjjuav (xtyrjaqeyx ) View more | - | 01 Jan 2014 | ||
SUSTAIN (ASCO2023) Manual | Phase 2 | 30 | (ackrsvdwhz) = Two pts discontinued silibinin-based nutraceutical assumption due to G1 nausea. No other adverse events were reported. qrylnijhqc (qeamolatce ) | Positive | 31 May 2023 | ||
Not Applicable | Osteoarthritis, Knee interleukin-1alpha | interleukin-8 | complement proteins C3 | 220 | (njwtlgjxep) = yughbrbmkz valdyejgux (dancvggnwl ) View more | Positive | 10 Jun 2009 | ||
(njwtlgjxep) = qrycvaoaby valdyejgux (dancvggnwl ) View more | |||||||
Not Applicable | - | zdvfxmdpfd(vfkolzqtrs) = smanxpgdcm xrcgecshmh (mfbyziyfsc ) View more | - | 15 Apr 2013 | |||
zdvfxmdpfd(vfkolzqtrs) = pbbjfzywpi xrcgecshmh (mfbyziyfsc ) View more |